OA12293A - 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. - Google Patents

3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. Download PDF

Info

Publication number
OA12293A
OA12293A OA1200200386A OA1200200386A OA12293A OA 12293 A OA12293 A OA 12293A OA 1200200386 A OA1200200386 A OA 1200200386A OA 1200200386 A OA1200200386 A OA 1200200386A OA 12293 A OA12293 A OA 12293A
Authority
OA
OAPI
Prior art keywords
alkyl
aryl
halogen
optionally substituted
substituted
Prior art date
Application number
OA1200200386A
Other languages
English (en)
Inventor
Bernard Joseph Banks
Douglas James Critcher
Ashley Edward Fenwick
David Morris Gethin
Stephen Paul Gibson
Graham Lunn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA12293A publication Critical patent/OA12293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200200386A 2000-06-23 2001-06-07 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. OA12293A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles

Publications (1)

Publication Number Publication Date
OA12293A true OA12293A (en) 2004-03-18

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200386A OA12293A (en) 2000-06-23 2001-06-07 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity.

Country Status (34)

Country Link
EP (1) EP1292574A1 (hu)
JP (1) JP2004512263A (hu)
KR (1) KR20040002386A (hu)
CN (1) CN1639121A (hu)
AP (1) AP2002002698A0 (hu)
AR (1) AR028969A1 (hu)
AU (1) AU781837B2 (hu)
BG (1) BG107329A (hu)
BR (1) BR0111867A (hu)
CA (1) CA2412188A1 (hu)
CZ (1) CZ20023967A3 (hu)
DO (1) DOP2001000187A (hu)
DZ (1) DZ3368A1 (hu)
EA (1) EA005117B1 (hu)
GB (1) GB0015562D0 (hu)
HR (1) HRP20020998A2 (hu)
HU (1) HUP0301228A3 (hu)
IL (1) IL153427A0 (hu)
IS (1) IS6637A (hu)
MA (1) MA26915A1 (hu)
MX (1) MXPA02012878A (hu)
NO (1) NO20026168L (hu)
NZ (1) NZ523141A (hu)
OA (1) OA12293A (hu)
PA (1) PA8519401A1 (hu)
PE (1) PE20020253A1 (hu)
PL (1) PL365956A1 (hu)
SK (1) SK17172002A3 (hu)
TN (1) TNSN01094A1 (hu)
UA (1) UA73176C2 (hu)
UY (1) UY26787A1 (hu)
WO (1) WO2001098267A1 (hu)
YU (1) YU91802A (hu)
ZA (1) ZA200210278B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1440059T3 (da) * 2001-10-22 2008-07-14 Pfizer Prod Inc 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
CA2486000A1 (en) * 2002-05-17 2003-11-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Use of compounds that are effective as selective opiate receptor modulators
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
JP4960217B2 (ja) * 2004-02-23 2012-06-27 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとして有用なアザビシクロ（３．１．０）ヘキサン誘導体
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
DE602006017543D1 (de) * 2005-06-14 2010-11-25 Glaxo Group Ltd Neue verbindungen
EP2010518B1 (en) 2006-04-03 2011-02-16 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
BRPI0809651A2 (pt) 2007-03-30 2014-10-07 Tioga Pharmaceuticals Inc Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
EP2995614B8 (en) 2010-06-11 2018-03-28 Rhodes Technologies Inc. Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
EP2621902B1 (en) 2010-09-28 2017-04-12 Panacea Biotec Ltd 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders
DK3072884T3 (da) * 2013-11-20 2020-03-09 Sanwa Kagaku Kenkyusho Co 3-azabicyclo[3.1.0]hexanderivat og anvendelse deraf til medicinske formål
CN107428687B (zh) 2015-05-20 2021-06-11 宇部兴产株式会社 一种3-氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用
EP3582783B1 (en) 2017-02-17 2023-06-07 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
US11702408B2 (en) 2017-02-17 2023-07-18 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CA3054122A1 (en) 2017-03-02 2018-09-07 Sanwa Kagaku Kenkyusho Co., Ltd. Therapeutic agent for alcohol use disorders
CN108250088B (zh) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 N，n，n′-三甲基-n′-羟乙基双氨基乙基醚的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
AR245933A1 (es) * 1987-04-16 1994-03-30 Lilly Co Eli Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales.
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
MA26915A1 (fr) 2004-12-20
HRP20020998A2 (en) 2004-02-29
SK17172002A3 (sk) 2004-09-08
ZA200210278B (en) 2003-12-19
GB0015562D0 (en) 2000-08-16
EA200201269A1 (ru) 2003-06-26
MXPA02012878A (es) 2003-05-14
JP2004512263A (ja) 2004-04-22
UA73176C2 (en) 2005-06-15
EA005117B1 (ru) 2004-10-28
AU6259101A (en) 2002-01-02
NO20026168L (no) 2003-02-18
CA2412188A1 (en) 2001-12-27
NO20026168D0 (no) 2002-12-20
HUP0301228A3 (en) 2005-08-29
AU781837B2 (en) 2005-06-16
BR0111867A (pt) 2003-07-01
IL153427A0 (en) 2003-07-06
KR20040002386A (ko) 2004-01-07
AR028969A1 (es) 2003-05-28
TNSN01094A1 (fr) 2005-11-10
WO2001098267A1 (en) 2001-12-27
CN1639121A (zh) 2005-07-13
AP2002002698A0 (en) 2002-12-31
NZ523141A (en) 2005-06-24
WO2001098267A8 (en) 2003-02-27
CZ20023967A3 (cs) 2004-02-18
PL365956A1 (en) 2005-01-24
BG107329A (en) 2003-07-31
IS6637A (is) 2002-11-28
YU91802A (sh) 2006-05-25
PA8519401A1 (es) 2002-12-30
DZ3368A1 (fr) 2001-12-27
UY26787A1 (es) 2002-01-31
DOP2001000187A (es) 2002-03-30
PE20020253A1 (es) 2002-04-08
EP1292574A1 (en) 2003-03-19
HUP0301228A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
CA2356300C (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
OA12293A (en) 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity.
JP2840448B2 (ja) インドール誘導体
JP2002504483A (ja) ヒスタミンｈ３受容体リガンド
EP2709985A1 (en) Amine derivatives as potassium channel blockers
AU2003276201A1 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
JP6434528B2 (ja) 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用
CA2794176C (en) Novel benzamide derivatives
JP2005504800A (ja) ピリミジノン化合物及びその薬剤として許容される塩の製造方法
US20020025948A1 (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
KR101800594B1 (ko) 미량 아민 결합 수용체(taar) 조절제로서 6-아미노-5,6,7,8-테트라하이드로나프탈렌-2-일 또는 3-아미노크로만-7-일 유도체
US20030207876A1 (en) 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
CA2287394A1 (en) Methods for synthesizing 2-substituted imidazoles
CA1294274C (en) Method of treating muscle tension, muscle spasticity and anxiety with 3-aryloxy-azetidinecarboxamides
CA2758367A1 (fr) Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
CA2751866A1 (fr) Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
CA2751863A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
CA2755526A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique